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Opioid receptors: Pinning down the opiate targets
Steven R. Childers
Recent studies of knockout mice conclusively show that
the mu opioid receptor mediates the analgesic effects
of morphine; they further suggest that the mu opioid
receptor also has a role in mediating the effects of
other opioid agonists, and provide insights into the
non-analgesic effects of mu opioids.
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Morphine, as derived from the opium poppy, has been
used in the treatment of pain and dysentery, and for its
euphoric properties, for thousands of years. Sir William
Osler referred to morphine as “God’s own medicine”, and
morphine is still a drug of choice in the treatment of
severe pain. Indeed, morphine remains the standard by
which new analgesics are measured. The identification of
the molecular target of morphine is, therefore, an impor-
tant research goal. Several decades of pharmacological
research pointed to the mu opioid receptor as the principal
target for morphine actions, but the recent development
of opioid receptor knockout mice has provided exciting
new tools to confirm this identity and to explore the
normal physiological functions of opioid receptors.
The application of molecular biological techniques to the
study of opioid receptors has gratifyingly given results that
closely parallel the traditional pharmacological data.
Opioid receptors, which are known to signal by coupling
to G proteins, have traditionally been grouped into three
major classes — mu, delta and kappa. This subdivision has
been supported by the results of cloning and analyzing the
receptor-encoding genes. First to be cloned was the delta
receptor gene, quickly followed by the genes for the mu
and kappa receptors, as well as for a related ‘orphan’
receptor variously named ORL1 or KOR-3 (reviewed in
[1]). These receptors turn out to be closely related in
sequence, the seven transmembrane regions characteristic
of G-coupled receptors being especially similar. Interest-
ingly, although pharmacological data suggest the major
classes of opioid receptors can be subdivided into several
subtypes, no evidence for separate opioid receptor
subtype genes has come from the molecular data.
Although pharmacological studies have suggested that mu
opioid receptors mediate the neuronal and non-neuronal
effects of morphine, the ability to ‘knockout’ the cloned
receptor genes in mice by targeted recombination in
embryonic stem cells offers a powerful new way of investi-
gating the physiological and pharmacological roles of the
opioid receptors. In the past year, several of these mutant
mice with inactivated opioid receptor genes have been
generated, with the most information so far coming from
studies of mice that lack mu opioid receptors. The con-
struction of these knockout mice depended upon cloning
and sequencing of the entire opioid receptor gene [2], and
was first reported by Matthes et al. [3] and Sora et al. [4]. 
The knockout mice show clear clear effects of lacking func-
tional mu opioid receptors. In all cases examined, effects
previously defined as mu-receptor-mediated are abolished
in the homozygous mutant mice. For example, ligand
binding to mu receptors, assayed either in membranes or in
brain sections by autoradiography, was reduced by approxi-
mately 50% in the heterozygous mice and was undetectable
in the homozygous mice. But, in the mutant mice, no
changes could be detected in binding of ligands specific for
delta or kappa receptors, or in the levels of mRNAs encod-
ing precursor proteins — pro-enkephalin, pro-dynorphin
and pro-opiomelanocortin — from which endogenous
opioid peptides are naturally derived. Most importantly, the
actions of morphine in a variety of assay systems were elimi-
nated in the homozygous mu receptor mutant mice (Table
1). In particular, acute morphine analgesia, as determined in
a variety of tests, was eliminated. Similarly, the production
of withdrawal symptoms following chronic morphine treat-
ment, and the reinforcing effects of morphine as deter-
mined in conditioned place preference tests, were also
eliminated in the mu receptor knockout mice.
To opioid pharmacologists all over the world, these
results were both comforting and somewhat surprising.
For many years, pharmacological assays — both in vivo
and in vitro — have suggested that morphine’s principal
biological actions occur through mu opioid receptors, and
the elimination of morphine effects in mu receptor
mutants confirms this pharmacological evidence in a sat-
isfyingly conclusive manner. The pharmacological evi-
dence also indicated, however, that morphine is not
highly selective in binding to mu receptors rather than
delta and kappa receptors; in fact, morphine is only 40
times more potent at mu receptors than at delta receptors.
It was somewhat surprising, therefore, that no delta-
receptor-mediated effects were observed in the mu
receptor mutant mice at high morphine doses. This result
could be explained by the attenuation of delta-receptor-
selective analgesia in the mu receptor mutants (see
below), or if the morphine doses were not high enough to
cause significant delta receptor activation in these mice.
Although the effects of morphine itself appear to be
eliminated in mu knockout mice, recent results of
Schuller et al. [5] suggest that some effects of opioids that
were previously thought to be mu-receptor-mediated may
be mediated by other receptors. Traditional pharmacologi-
cal evidence has long suggested that the actions of the
heroin are caused by deacetylation of heroin to form mor-
phine in the brain, where it acts at mu receptors. However,
recent studies have shown that heroin and morphine anal-
gesia are blocked by different antisense oligonucleotides
to the mu receptor [6]. Interestingly, in the mu receptor
knockout mice, where morphine analgesia is eliminated,
heroin analgesia is only partially attenuated [5]. The authors
infer from their results the existence of a distinct heroin
receptor, which must be related structurally to the mu
receptor given that the antisense oligonucleotides that
blocked heroin analgesia were based on the nucleotide
sequence that encodes the mu receptor. 
These results present an interesting paradox, however. If
the heroin receptor is a product of the mu receptor gene,
then how can heroin analgesia be maintained in a knock-
out mouse that lacks a functional mu receptor gene?
Schuller et al. [5] suggest that alternative splice variants of
the mu receptor mRNA — the existence of which is a dis-
tinct possibility because of the existence of several introns
within the coding region of the mu receptor gene — may
still be produced in the mu receptor knockout mice. This
conclusion is likely to be controversial, as the presence of
opioid receptor splice variants has been difficult to confirm
directly. Future examination of heroin effects in mu knock-
out mice from different laboratories — especially where
the knockouts were prepared by manipulating different
parts of the mu receptor gene — should help to clarify this
puzzling issue.
Interesting effects have been observed in mice that
are heterozygous for a targeted mutation of the mu recep-
tor gene, mice that make half of the normal complement
of mu receptors (G.R. Uhl, personal communication).
Whereas the homozygous mutant mice displayed no
detectable effects of morphine in a variety of tests, the
heterozygous animals displayed increased morphine rein-
forcement (as determined by conditioned place prefer-
ence), and unchanged levels of physical dependence and
morphine tolerance compared to wild-type mice. The
various physiological effects of morphine are, therefore,
not each related in a stoichiometric way to the number of
mu receptors. Although there are several possible expla-
nations for these differences, Uhl and colleagues favour
the view that they are indicative of the different receptor
levels — that is, the receptor reserve — required for the
various different physiological effects of morphine.
What are the effects of mu receptor deficiency on the
physiological actions mediated by other opioid receptor
types? The answer is also somewhat surprising. Studies of
delta opioid analgesia, using the delta-selective analogs
BUBU [3] and DPDPE [7], revealed that delta analgesia
was, like morphine analgesia, profoundly reduced in the
mu receptor knockout mice (Table 1). This is confusing,
as receptor binding data clearly showed that delta recep-
tors are expressed normally in the mu receptor mutants, at
least in some brain regions. These results may indicate
that neuronal circuits employing mu receptors have a role
in delta analgesia, as suggested by Sora et al. [7]. Interest-
ingly, preliminary results (B. Kieffer, personal communi-
cation) show that the efficacy of delta receptor coupling to
G proteins may be reduced in the spinal cord of mu recep-
tor knockout mice, suggesting that lack of mu receptors
may affect the functioning of the delta opioid system
without any discernible change in the number of delta
receptors themselves.
An important question that can be addressed in opioid
receptor knockout mice is the role of the receptors in
normal — non-drug-induced — physiology and behavior.
In analgesia testing, the mu receptor mutants displayed
decreased baseline latencies in ‘tailflick’ assays, suggest-
ing increased nociception (pain) sensitivity [4]. In addition
to their role in mediating analgesia, mu receptors have
long been implicated in other processes, such as gastroin-
testinal motility, respiratory control, motor activity and
hormonal regulation. As mentioned above, the mu knock-
out mice did not exhibit any major developmental defects.
In a recent study by Tian et al. [8], however, several other
parameters appeared to be altered in these mutant mice.
For example, the homozygotes showed reduced locomotor
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Table 1
Physiological effects of mu opioid receptor deficiency.
Measure Effect Reference
Morphine* analgesia Blocked [3,4]
Morphine reinforcement† Blocked [3]
Chronic morphine tolerance Blocked [3]
Chronic morphine withdrawal Blocked [3]
DPDPE, BUBU‡ analgesia Blocked [3,7]
Heroin analgesia Partial reduction [5]
Basal nociception Increased [4]
Basal locomotor activity Decreased [8]
Basal sexual activity Decreased [8]
Immune cell activity Increased [8]
*Morphine is considered to be a mu-receptor-specific agonist. †This is
based on a conditioned place preference test. ‡DPDPE and BUBU are
thought to be delta-receptor-specific agonists.
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activity compared to wild-type, and the increase in motor
activity normally observed after administration of mor-
phine was not evident in the knockout mice. These
effects are not surprising, considering the relatively high
density of mu opioid receptors in the striatum, a brain area
known to be important in regulating motor activity. 
Other abnormalities of the mu knockout mice were
surprising, however, especially changes in sexual behavior
(the level of which was unusually low in the mutants) and
in immune responses (the proliferation of immune progen-
itor cells was increased in the mutants). As in any work
with knockout mice, these conclusions must be tempered
by the possibility that the results may be influenced by
non-specific adaptive changes caused by inactivation of
the mu receptor gene. Nevertheless, these results demon-
strate how transgenic methodologies have the potential to
reveal physiological roles of receptors that may not have
been predicted from standard pharmacological approaches.
At the recent International Narcotics Research Confer-
ence (Hong Kong, August, 1997), several groups reported
preliminary data on  the effects of opioids in knockout
mice lacking either delta or kappa opioid receptors. In
delta receptor knockout mice (J. Pintar, personal commu-
nication), the effects on delta-mediated analgesia depended
upon the route of drug administration: intra-cerebral, but
not spinal, delta analgesia was maintained in the delta
knockout animals. These results point out the important
differences that have often been noted about mechanisms
of analgesia, depending upon the route and dose of
agonist administration. In kappa receptor knockout mice
(B. Kieffer, personal communication), kappa, but not mor-
phine, analgesia was blocked. Interestingly, the kappa
knockout mice also displayed increased baseline pain in a
writhing test, suggesting that kappa receptors may have a
role in modulating intrinsic pain sensitivity.
Future studies with other receptor knockout mice may
reveal other interesting aspects of opioid action. For
example, at the conference in Hong Kong, results
presented by R. Maldonado (University René Descartes,
Paris) showed significant alterations in opioid effects in
dopamine D2 receptor knockout mice. While morphine
analgesia appeared normal in these mice, morphine re-
inforcement was significantly attenuated in the D2
homozygous animals. If these preliminary results are con-
firmed, then they would provide important direct evi-
dence for the role of dopaminergic systems in mediating
opioid reward mechanisms.
In summary, several points can be made about this first
round of data from opioid receptor knockout mice. First,
and most important, most of the studies are still at an early
stage, and conclusions will undoubtedly be affected by a
number of factors, including the genetic backgrounds of
the knockout mice, the methods of biological testing, and
the routes of administration of test drugs. For these
reasons, discrepancies between laboratories are to be
expected. The conclusions must also be cautious because
of the real possibility of non-specific neuroadaptive
changes that may occur in response to the loss of a specific
gene throughout development. In future, the develop-
ment of conditionally-deficient knockout mice will help to
address this important issue. In the meantime, while the
opioid receptor knockout mice have clearly determined
the site of action of one opioid drug — morphine  — they
have brought into question the role of specific opioid
receptors in mediating other opioid effects, and opened
new areas of speculation about the role of these receptors
in mediating normal physiological functions.
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